fbpx

Grey Wolf Therapeutics completes £2.5 million Series A2 financing to accelerate development of therapies targeting ERAP2

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for...